Cargando…

The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis

BACKGROUND: Liraglutide has been shown to improve glucose tolerance and lose weight in individuals with type 2 diabetes. To date, no meta-analysis of liraglutide's safety and efficacy in individuals without diabetes has been conducted. OBJECTIVES: The aim of this study is to carry out a meta-an...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Pei, Liu, Yu, Ren, Yuan, Bai, Jie, Zhang, Guangzhen, Cui, Yuanshan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Makerere Medical School 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040262/
https://www.ncbi.nlm.nih.gov/pubmed/32127832
http://dx.doi.org/10.4314/ahs.v19i3.35
_version_ 1783500948278083584
author Zhang, Pei
Liu, Yu
Ren, Yuan
Bai, Jie
Zhang, Guangzhen
Cui, Yuanshan
author_facet Zhang, Pei
Liu, Yu
Ren, Yuan
Bai, Jie
Zhang, Guangzhen
Cui, Yuanshan
author_sort Zhang, Pei
collection PubMed
description BACKGROUND: Liraglutide has been shown to improve glucose tolerance and lose weight in individuals with type 2 diabetes. To date, no meta-analysis of liraglutide's safety and efficacy in individuals without diabetes has been conducted. OBJECTIVES: The aim of this study is to carry out a meta-analysis to assess the efficacy and safety of liraglutide in the obese, non-diabetic individuals. METHODS: A literature review was performed to identify all published randomised control trials (RCT) of liraglutide for the treatment of obesity in non-diabetic individuals. The search included the following databases: EMBASE, MEDLINE and the Cochrane Controlled Trials Register. RESULTS: We included five publications involving a total of 4,754 patients that compared liraglutide with placebo and found that liraglutide to be an effective and safe treatment for weight loss in individuals without diabetes. Primary efficacy end points: mean weight loss (MD = -5.52, 95% CI = -5.93 to -5.11, p<0.00001); lost more than 5% of body weight (OR = 5.46, 95% CI=3.57 to 8.34, p<0.00001) and key secondary efficacy end points: SBP decreased (the MD = -2.56, 95% CI = -3.28 to -1.84, p<0.00001). Safety assessments included the proportion of individuals who were withdrawn due to AE (OR = 2.85, 95% CI= 0.84 to 9.62, p=0.009), and nausea indicated that liraglutide was well tolerated. CONCLUSION: This systematic review and meta-analysis indicates that liraglutide to be an effective and safe treatment for weight loss in the obese, non-diabetic individuals.
format Online
Article
Text
id pubmed-7040262
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Makerere Medical School
record_format MEDLINE/PubMed
spelling pubmed-70402622020-03-03 The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis Zhang, Pei Liu, Yu Ren, Yuan Bai, Jie Zhang, Guangzhen Cui, Yuanshan Afr Health Sci Articles BACKGROUND: Liraglutide has been shown to improve glucose tolerance and lose weight in individuals with type 2 diabetes. To date, no meta-analysis of liraglutide's safety and efficacy in individuals without diabetes has been conducted. OBJECTIVES: The aim of this study is to carry out a meta-analysis to assess the efficacy and safety of liraglutide in the obese, non-diabetic individuals. METHODS: A literature review was performed to identify all published randomised control trials (RCT) of liraglutide for the treatment of obesity in non-diabetic individuals. The search included the following databases: EMBASE, MEDLINE and the Cochrane Controlled Trials Register. RESULTS: We included five publications involving a total of 4,754 patients that compared liraglutide with placebo and found that liraglutide to be an effective and safe treatment for weight loss in individuals without diabetes. Primary efficacy end points: mean weight loss (MD = -5.52, 95% CI = -5.93 to -5.11, p<0.00001); lost more than 5% of body weight (OR = 5.46, 95% CI=3.57 to 8.34, p<0.00001) and key secondary efficacy end points: SBP decreased (the MD = -2.56, 95% CI = -3.28 to -1.84, p<0.00001). Safety assessments included the proportion of individuals who were withdrawn due to AE (OR = 2.85, 95% CI= 0.84 to 9.62, p=0.009), and nausea indicated that liraglutide was well tolerated. CONCLUSION: This systematic review and meta-analysis indicates that liraglutide to be an effective and safe treatment for weight loss in the obese, non-diabetic individuals. Makerere Medical School 2019-09 /pmc/articles/PMC7040262/ /pubmed/32127832 http://dx.doi.org/10.4314/ahs.v19i3.35 Text en © 2019 Zhang et al. Licensee African Health Sciences. This is an Open Access article distributed under the terms of the Creative commons Attribution License (https://creativecommons.org/licenses/BY/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Articles
Zhang, Pei
Liu, Yu
Ren, Yuan
Bai, Jie
Zhang, Guangzhen
Cui, Yuanshan
The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis
title The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis
title_full The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis
title_fullStr The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis
title_full_unstemmed The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis
title_short The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis
title_sort efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040262/
https://www.ncbi.nlm.nih.gov/pubmed/32127832
http://dx.doi.org/10.4314/ahs.v19i3.35
work_keys_str_mv AT zhangpei theefficacyandsafetyofliraglutideintheobesenondiabeticindividualsasystematicreviewandmetaanalysis
AT liuyu theefficacyandsafetyofliraglutideintheobesenondiabeticindividualsasystematicreviewandmetaanalysis
AT renyuan theefficacyandsafetyofliraglutideintheobesenondiabeticindividualsasystematicreviewandmetaanalysis
AT baijie theefficacyandsafetyofliraglutideintheobesenondiabeticindividualsasystematicreviewandmetaanalysis
AT zhangguangzhen theefficacyandsafetyofliraglutideintheobesenondiabeticindividualsasystematicreviewandmetaanalysis
AT cuiyuanshan theefficacyandsafetyofliraglutideintheobesenondiabeticindividualsasystematicreviewandmetaanalysis
AT zhangpei efficacyandsafetyofliraglutideintheobesenondiabeticindividualsasystematicreviewandmetaanalysis
AT liuyu efficacyandsafetyofliraglutideintheobesenondiabeticindividualsasystematicreviewandmetaanalysis
AT renyuan efficacyandsafetyofliraglutideintheobesenondiabeticindividualsasystematicreviewandmetaanalysis
AT baijie efficacyandsafetyofliraglutideintheobesenondiabeticindividualsasystematicreviewandmetaanalysis
AT zhangguangzhen efficacyandsafetyofliraglutideintheobesenondiabeticindividualsasystematicreviewandmetaanalysis
AT cuiyuanshan efficacyandsafetyofliraglutideintheobesenondiabeticindividualsasystematicreviewandmetaanalysis